Cytoplasmic expression of HuR may be a valuable diagnostic tool for determining the potential for malignant transformation of oral verrucous borderline lesions

Oncology Reports

Volumn 31, Issue 4, 2014, Pages 1547-1554

  Habiba, Umma ^a   Kitamura, Tetsuya ^a   Yanagawa Matsuda, Aya ^a   Hida, Kyoko ^a   Higashino, Fumihiro ^a   Ohiro, Yoichi ^a   Totsuka, Yasunori ^a   Shindoh, Masanobu ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

Author keywords

HuR protein; Molecular diagnosis; Oral verrucous lesion

Indexed keywords

HUR PROTEIN; KI 67 ANTIGEN; PROTEIN P53;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOPLASM; DISEASE ASSOCIATION; DISEASE MARKER; DISEASE SEVERITY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOCHEMISTRY; MALE; MALIGNANT TRANSFORMATION; MIDDLE AGED; MOLECULAR DIAGNOSTICS; MOUTH CARCINOMA; MOUTH DISEASE; ORAL VERRUCOUS HYPERPLASIA; ORAL VERRUCOUS LESION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; VERRUCOUS CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, VERRUCOUS; CELL TRANSFORMATION, NEOPLASTIC; CYTOPLASM; FEMALE; HU PARANEOPLASTIC ENCEPHALOMYELITIS ANTIGENS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MOUTH NEOPLASMS; PRECANCEROUS CONDITIONS; TUMOR MARKERS, BIOLOGICAL;

EID: 84908135879     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2014.3017     Document Type: Article

References (25)

1. Ackerman LV: Verrucous carcinoma of the oral cavity. Surgery 23: 670-678, 1948.
2. Fertilo A and Recher G: Ackerman's tumor (verrucous carcinoma) of the larynx: a clinicopathologic study of 77 cases. Cancer 46: 1617-1630, 1980.
3. Batsakis JG, Hybels R, Crissman JD and Rice DH: The pathology of head and neck tumors: verrucous carcinoma, Part 15. Head Neck Surg 5: 29-38, 1982.
4. Medina JE, Dichtel W and Luna MA: Verrucous-squamous carcinomas of the oral cavity. A clinicopathological study of 104 cases. Arch Otolaryngol 110: 437-440, 1984.
5. Rebane A, Aab A and Steitz JA: Transportin 1 and 2 are redundant nuclear import factors for hnRNP A1 and HuR. RNA 10: 590-599, 2004.
6. Fan XC and Steitz JA: HNS, a nuclear-cytoplasmic shuttling sequence in HuR. Proc Natl Acad Sci USA 95: 15293-15298, 1998.
7. Brennan CM, Gallouzi IE and Steitz JA: Protein ligands to HuR modulate its interaction with target mRNAs in vivo. J Cell Biol 151: 1-14, 2000.
8. Erkinheimo TL, Lassus H, Sivula A, et al: Cytoplasmic HuR expression correlates with poor outcome and with cyclooxygenase 2 expression in serous ovarian carcinoma. Cancer Res 63: 7591-7594, 2003.
9. Denkert C, Weichert W, Pest S, et al: Overexpression of the embryonic-lethal abnormal vision-like protein HuR in ovarian carcinoma is a prognostic factor and is associated with increased cyclooxygenase 2 expression. Cancer Res 64: 189-195, 2004.
10. Hasegawa H, Kakuguchi W, T Kuroshima T, et al: HuR is exported to the cytoplasm in oral cancer cells in a different manner from that of normal cells. Br J Cancer 100: 1943-1948, 2009.
11. Szymańska K and Hainaut P: TP53 and mutations in human cancer. Acta Biochim Pol 50: 231-238, 2003.
12. Pavelic ZP, Li YQ, Stambrook PJ, et al: Overexpression of p53 protein is common in premalignant head and neck lesions. Anticancer Res 14: 2259-2266, 1994.
13. Shin DM, Kim J, Ro JY, Hittelman J, Roth JA, Hong WK and Hittelman WN: Activation of p53 gene expression in premalignant lesions during head and neck tumorigenesis. Cancer Res 54: 321-326, 1994.
14. Wang LD, Shi ST, Zhou Q, et al: Changes in p53 and cyclin D1 protein levels and cell proliferation in different stages of human esophageal and gastric-cardia carcinogenesis. Int J Cancer 59: 514-519, 1994.
15. MacCallum DE and Hall PA: The location of pKi67 in the outer dense fibrillary compartment of the nucleolus points to a role in ribosome biogenesis during the cell division cycle. J Pathol 190: 537-544, 2000.
16. Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U and Stein H: Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 133: 1710-1715, 1984.
17. Braun N, Papadopoulos T and Müller-Hermelink HK: Cell cycle dependent distribution of the proliferation-associated Ki-67 antigen in human embryonic lung cells. Virchows Arch B Cell Pathol Incl Mol Pathol 56: 25-33, 1988.
18. Woźniak A, Golusiński W, Kaczmarek E, Kaczmarek J and Kaczmarek J: Prognostic significance of Ki 67 and PCNA expression in laryngeal squamous cell carcinoma (morphometric evaluation of labelling index-L1). Otolaryngol Pol 56: 437-443, 2002 (In Polish).
19. Gimenez-Conti IB, Collet AM, Lanfranchi H, et al: p53, Rb, and cyclin D1 expression in human oral verrucous carcinomas. Cancer 8: 17-23, 1996.
20. Saito T, Nakajima T and Mogi K: Immunohistochemical analysis of cell cycle-associated proteins p16, pRb, p53, p27 and Ki-67 in oral cancer and precancer with special reference to verrucous carcinomas. J Oral Pathol Med 28: 226-232, 1999.
21. Cho NP, Han HS, Soh Y, Lee KY and Son HJ: Cytoplasmic HuR over-expression is associated with increased cyclooxygenase-2 expression in laryngeal squamous cell carcinomas. Pathology 39: 545-550, 2007.
22. Cho NP, Han HS, Soh Y and Son HJ: Overexpression of cyclooxygenase-2 correlates with cytoplasmic HuR expression in salivary mucoepidermoid carcinoma but not in pleomorphic adenoma. J Oral Pathol Med 36: 297-303, 2007.
23. Heinonen M, Bono P, Narko K, et al: Cytoplasmic HuR expression is a prognostic factor in invasive ductal breast carcinoma. Cancer Res 65: 2157-2161, 2005.
24. Niesporek S, Kristiansen G, Thoma A, et al: Expression of the ELAV-like protein HuR in human prostate carcinoma is an indicator of disease relapse and linked to COX-2 expression. Int J Oncol 32: 341-347, 2008.
25. Gallouzi IE and Steitz JA: Delineation of mRNA export pathways by the use of cell-permeable peptides. Science 294: 1895-1901, 2001.